



(51) International Patent Classification:

C12Q 1/6874 (2018.01) *G16B 35/10* (2019.01)
C12Q 1/6886 (2018.01) *A61K 39/395* (2006.01)
G01N 33/68 (2006.01) *A61P 35/00* (2006.01)
G16B 30/10 (2019.01) *C12N 15/11* (2006.01)

(21) International Application Number:

PCT/US2025/012147

(22) International Filing Date:

17 January 2025 (17.01.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/621,749 17 January 2024 (17.01.2024) US

(71) Applicant: **THE JOHNS HOPKINS UNIVERSITY**

[US/US]; 3400 North Charles Street, Baltimore, Maryland 21218 (US).

(72) Inventors: **VELCULESCU, Victor E.**; 3627 Broadleaf

Ct., Glenwood, Maryland 21738 (US). **MEDINA, Jamie**;
3400 North Charles Street, Baltimore, Maryland 21218 (US). **SCHARPF, Robert B.**; 303 Edgevale Rd, Baltimore, Maryland 21210 (US).

(74) Agent: **CORLESS, Peter F.** et al.; 212 Carnegie Center, Suite 400, Princeton, 08540 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS FOR DETERMINING RESPONSIVENESS TO CANCER THERAPY




FIG. 1A

(57) Abstract: A cell-free DNA fragmentome method (DELFI-TF) is described to evaluate circulating tumor fraction during therapy. DELFI-TF rapidly determined disease progression in patients receiving immunotherapy.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*